An ultra‐long‐acting recombinant insulin for the treatment of diabetes mellitus in cats

BACKGROUND: Treatment of diabetes mellitus (DM) in cats typically requires insulin injections q12h‐q24h, posing a major compliance barrier for caregivers. Novel treatments enabling decreased injection frequency while maintaining safety are highly desirable. Insulin fused with feline immunoglobulin f...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilor, Chen, Hulsebosch, Sean E., Pires, Jully, Bannasch, Michael J., Lancaster, Thomas, Delpero, Andrea, Ragupathy, Ramya, Murikipudi, Sylaja, Zion, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
SMALL ANIMAL
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478034/
https://www.ncbi.nlm.nih.gov/pubmed/34190365
http://dx.doi.org/10.1111/jvim.16150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478034/
https://www.ncbi.nlm.nih.gov/pubmed/34190365
http://dx.doi.org/10.1111/jvim.16150

Ejemplares similares